BridgeMD
New treatment option for Chronic Lymphocytic Leukemia (CLL)
Official title Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
ClinicalTrials.gov ID: NCT04895436
What this study is testing
What is Venetoclax?
Venetoclax is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for chronic lymphocytic leukemia (cll).
Also referred to as Venclexta, ABT-199.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess retreatment with venetoclax-obinutuzumab (VenG) in participants previously treated with fixed duration first-line (IL) therapy of venetoclax in combination with an anti-CD20 antibody +/- X (where X is any additional drug).
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Documented diagnosis of chronic lymphocytic leukemia (CLL) that requires treatment for CLL according to International Workshop for Chronic...
- Previously completed venetoclax + anti-CD20 antibody +/- X regimen as a fixed duration first-line (1L) therapy and achieved documented response...
- More than 24 months (Cohort 1) or 12-24 months (Cohort 2) have elapsed between last dose of venetoclax and disease progression after completion of 1L...
You likely can't join if
- \- Received intervening treatment for CLL after completing previous treatment with a venetoclax + anti-CD20 antibody +/- X regimen.
The study team makes the final eligibility decision.
Where it's taking place
- La Jolla, California, United States
- Atlanta, Georgia, United States
- Des Moines, Iowa, United States
- Boston, Massachusetts, United States
- Detroit, Michigan, United States
- Duluth, Minnesota, United States
- Hattiesburg, Mississippi, United States
- Florham Park, New Jersey, United States
- Hackensack, New Jersey, United States
- Chapel Hill, North Carolina, United States
- Charlotte, North Carolina, United States
- Winston-Salem, North Carolina, United States
- Columbus, Ohio, United States
- Philadelphia, Pennsylvania, United States
- Madison, Wisconsin, United States
- Adelaide, South Australia, Australia
- Epping, Victoria, Australia
- Melbourne, Victoria, Australia
- Sankt Pölten, Lower Austria, Austria
- Vienna, State of Vienna, Austria
+ 36 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include La Jolla, California, United States; Atlanta, Georgia, United States; Des Moines, Iowa, United States; Boston, Massachusetts, United States; Detroit, Michigan, United States; Duluth, Minnesota, United States and 50 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.